A comparison of singlet oxygen explicit dosimetry (SOED) and singlet oxygen luminescence dosimetry (SOLD) for photofrin-mediated photodynamic therapy

Kim, M. M., Penjweini, R., Gemmell, N. R., Veilleux, I., McCarthy, A., Buller, G. S., Hadfield, R. H. , Wilson, B. C. and Zhu, T. C. (2016) A comparison of singlet oxygen explicit dosimetry (SOED) and singlet oxygen luminescence dosimetry (SOLD) for photofrin-mediated photodynamic therapy. Cancers, 8(12), p. 109. (doi: 10.3390/cancers8120109) (PMID:27929427)

[img]
Preview
Text
132464.pdf - Published Version
Available under License Creative Commons Attribution.

2MB

Abstract

Accurate photodynamic therapy (PDT) dosimetry is critical for the use of PDT in the treatment of malignant and nonmalignant localized diseases. A singlet oxygen explicit dosimetry (SOED) model has been developed for in vivo purposes. It involves the measurement of the key components in PDT—light fluence (rate), photosensitizer concentration, and ground-state oxygen concentration ([3O2])—to calculate the amount of reacted singlet oxygen ([1O2]rx), the main cytotoxic component in type II PDT. Experiments were performed in phantoms with the photosensitizer Photofrin and in solution using phosphorescence-based singlet oxygen luminescence dosimetry (SOLD) to validate the SOED model. Oxygen concentration and photosensitizer photobleaching versus time were measured during PDT, along with direct SOLD measurements of singlet oxygen and triplet state lifetime (τΔ and τt), for various photosensitizer concentrations to determine necessary photophysical parameters. SOLD-determined cumulative [1O2]rx was compared to SOED-calculated [1O2]rx for various photosensitizer concentrations to show a clear correlation between the two methods. This illustrates that explicit dosimetry can be used when phosphorescence-based dosimetry is not feasible. Using SOED modeling, we have also shown evidence that SOLD-measured [1O2]rx using a 523 nm pulsed laser can be used to correlate to singlet oxygen generated by a 630 nm laser during a clinical malignant pleural mesothelioma (MPM) PDT protocol by using a conversion formula

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Gemmell, Mr Nathan and Hadfield, Professor Robert
Authors: Kim, M. M., Penjweini, R., Gemmell, N. R., Veilleux, I., McCarthy, A., Buller, G. S., Hadfield, R. H., Wilson, B. C., and Zhu, T. C.
College/School:College of Science and Engineering > School of Engineering > Electronics and Nanoscale Engineering
Journal Name:Cancers
Publisher:MDPI
ISSN:2072-6694
ISSN (Online):2072-6694
Published Online:06 December 2016
Copyright Holders:Copyright © 2016 The Authors
First Published:First published in Cancers 8(12):109
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
6672319UK Quantum Technology Hub in Enhanced Quantum ImagingMiles PadgettEngineering & Physical Sciences Research Council (EPSRC)EP/M01326X/1S&E P&A - PHYSICS & ASTRONOMY